NCT04475588View on ClinicalTrials.gov

Efficacy and Safety of Itolizumab in COVID-19 Complications

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

July 7, 2020

Study Completion Date

July 7, 2020

Conditions
Acute Respiratory Distress SyndromeCytokine Release SyndromeCovid19
Interventions
DRUG

Itolizumab IV infusion

"First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B"

DRUG

Best supportive care (BSC)

Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc

Trial Locations (4)

110002

MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital, New Delhi

110029

All India Institute Of Medical Sciences, New Delhi

400008

Topiwala National Medical College & B. Y. L. Nair Charitable Hospital,, Mumbai

400012

Seth GS Medical College and KEM Hospital, Mumbai

All Listed Sponsors
lead

Biocon Limited

INDUSTRY

NCT04475588 - Efficacy and Safety of Itolizumab in COVID-19 Complications | Biotech Hunter | Biotech Hunter